Some ERBB family inhibitors, such as Lapatinib and Afatinib are also developed for treatment of ERBB2+ breast cancer or GC (Geuna et al., 2012; Huang and Rizzo, 2012; Lin et al., 2012; Schuler et al., 2012; Hecht et al., 2016). This evidence concerns the gene EGFR and breast carcinoma.